Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Drug Interactions Significantly Reduce Targeted Therapy Efficacy

March 16th 2012

The DDIs between Co-Rx medications and targeted OAD is associated with a significant decrease in effectiveness and increased toxicity.

Dr. Perez-Soler on the Future of Lung Cancer Therapies

March 13th 2012

Dr. Roman Perez-Soler, from Albert Einstein College of Medicine, on the Future of Lung Cancer Therapies

Taking a Leap in Cancer Diagnostics: Clarient Enters New Era in Molecular Tumor Testing, Drug Discovery Research

March 9th 2012

Clarient provides more than 350 diagnostic tests to assess and characterize tumors, including tests for BRAF, KRAS, and EGFR gene mutations.

Dr. Belani Discusses Driver Mutations in NSCLC

March 7th 2012

Dr. Chandra Belani from Penn State Hershey Cancer Institute Discusses Driver Mutations in NSCLC

Dr. Ramaswamy Discusses Tumor Heterogeneity

March 7th 2012

Dr. Sridhar Ramaswamy from the Massachusetts General Hospital Cancer Center Discusses Tumor Heterogeneity

The Retreatment Strategy: Would It Work With the Same Molecularly Targeted Therapy?

February 23rd 2012

Patients who initially exhibit a response to a particular strategy may achieve substantial clinical benefit if the same or very similar agents are delivered after variably defined treatment-free intervals.

Dr. Leyland-Jones Discusses Genome Sequencing

February 20th 2012

Dr. Brian Leyland-Jones from Winship Cancer Institute Discusses Genome Sequencing

Dr. Bloom Explains Situations Requiring HER2 Retesting

February 16th 2012

Dr. Kenneth Bloom, from Chief Medical Officer at Clarient, Explains Situations Requiring HER2 Retesting

John Theurer Cancer Center at Hackensack University Medical Center: Providing Extraordinary Care to the Community

February 14th 2012

Year after year, the John Theurer Cancer Center (JTCC) harnesses the newest technologies and retains world-class oncologists, nurses, and scientists to fulfill its mission of delivering extraordinary care to patients in the community.

Dr. Ramaswamy on Dormant Tumor Cells and Resistance

February 13th 2012

Dr. Sridhar Ramaswamy, from Massachusetts General Hospital Cancer Center, on Dormant Tumor Cells and Resistance

Dr. Burris Discusses the Stratification of Clinical Trials

February 8th 2012

Dr. Howard Burris, from the Sarah Cannon Research Institute, Discusses the Stratification of Clinical Trials

Dr. Baselga on the Basis Behind the BOLERO-2 Trial

February 7th 2012

Dr. Jose Baselga, from Massachusetts General Hospital, Describes the Basis Behind the BOLERO-2 Trial

Dr. Cohen on mTOR Inhibition in Head and Neck Cancer

February 3rd 2012

Dr. Ezra Cohen, from University of Chicago, on mTOR Inhibition in Head and Neck Cancer

Dr. Ramaswamy on Targeting Dormant Cancer Cells

February 1st 2012

Dr. Sridhar Ramaswamy, from Massachusetts General Hospital Cancer Center, on Targeting Dormant Cancer Cells

Dr. Burris Discusses Targeting the mTOR Pathway

January 31st 2012

Dr. Howard Burris, from the Sarah Cannon Research Institute, Discusses Targeting the mTOR Pathway

Dr. Cohen Addresses the Role of the Hedgehog Pathway

January 30th 2012

Dr. Deirdre Cohen, from NYU Medical Oncology Associates, Addresses the Role of the Hedgehog Pathway

Dr. Bloom Compares HER2 Screening Assays

January 30th 2012

Dr. Kenneth Bloom, the Chief Medical Officer at Clarient, Compares HER2 Screening Assays

Noted Researcher Sees ERT as Remarkable Beginning

January 26th 2012

The treatment of Gaucher disease is poised to enter a new era as a result of advances in the understanding of the cellular pathways at work in the disorder.

Dr. Berenson Discusses Early Phase Proteasome Inhibitors

January 24th 2012

Dr. James Berenson, from the Institute for Myeloma and Bone Cancer Research, Discusses Early Phase Proteasome Inhibitors

Changing Paradigms for NSCLC in Personalized Therapy Era

January 20th 2012

With the discovery of mutation drivers for NSCLC--including EGFR, KRAS, and EMLA 4-ALK--targeted therapies directed to those mutations are beginning to make a difference.